• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Business Officer Ramachandran Niro Ph.D covered exercise/tax liability with 5,904 shares, decreasing direct ownership by 2% to 289,520 units (SEC Form 4)

    3/4/25 5:02:35 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ramachandran Niro Ph.D

    (Last) (First) (Middle)
    C/O AKOYA BIOSCIENCES, INC.
    100 CAMPUS DRIVE, 6TH FLOOR

    (Street)
    MARLBOROUGH MA 01752

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Akoya Biosciences, Inc. [ AKYA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Business Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/01/2025 F 2,310(1) D $1.63 293,114 D
    Common Stock 03/01/2025 F 3,594(2) D $1.63 289,520 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares withheld to cover taxes on a restricted stock unit award previously granted on February 23, 2023, which vests in four (4) annual equal installments beginning on March 1, 2024 and annually thereafter until fully vested.
    2. Represents shares withheld to cover taxes on a restricted stock unit award previously granted on February 22, 2024, which vests in four (4) annual equal installments beginning on March 1, 2025 and annually thereafter until fully vested.
    /s/ Niro Ramachandran, Ph.D., by Brian McKelligon, as Attorney-in-Fact 03/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AKYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKYA

    DatePrice TargetRatingAnalyst
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    8/6/2024Buy → Neutral
    BTIG Research
    8/6/2024Overweight → Neutral
    JP Morgan
    6/21/2024$7.50Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$14.00Buy
    UBS
    More analyst ratings

    $AKYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akoya Biosciences downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

      11/15/24 8:33:16 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by Morgan Stanley

      Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

      8/6/24 12:17:30 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by BTIG Research

      BTIG Research downgraded Akoya Biosciences from Buy to Neutral

      8/6/24 6:28:51 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

      It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

      4/30/25 8:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix and Akoya Biosciences Announce Amended Merger Agreement

      Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ:AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9 million fewer

      4/29/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      11/4/24 7:39:24 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Akoya BioSciences Inc.

      SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

      8/28/24 10:45:17 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      2/14/24 4:09:03 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Akoya Biosciences Announces Leadership Transition

      Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

      3/20/23 4:00:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

      MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

      2/28/23 8:00:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

      MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

      4/19/22 8:05:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Akoya BioSciences Inc.

      10-Q - Akoya Biosciences, Inc. (0001711933) (Filer)

      5/12/25 7:43:33 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Akoya BioSciences Inc.

      425 - Akoya Biosciences, Inc. (0001711933) (Subject)

      5/12/25 4:11:23 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akoya Biosciences, Inc. (0001711933) (Filer)

      5/12/25 4:10:15 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Ek John Frederick covered exercise/tax liability with 16,432 shares, decreasing direct ownership by 6% to 248,202 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      4/3/25 5:14:37 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Mckelligon Brian covered exercise/tax liability with 7,550 shares, decreasing direct ownership by 2% to 420,126 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:34:07 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Business Officer Ramachandran Niro Ph.D covered exercise/tax liability with 2,310 shares, decreasing direct ownership by 0.80% to 287,210 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:32:42 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Financials

    Live finance-specific insights

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

      MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

      3/17/25 4:00:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

      Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

      1/10/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials